Company intelligence / Profile preview

Synphora AB

Uppsala, Uppsala County, Swedencrunchbase.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Synphora was founded by inventors of latanoprost, a successful prostaglandin analogue used in glaucoma treatment. The company focuses on prostaglandin-based drug development primarily through outsourcing. It currently has two clinical-stage projects including JB991 for psoriasis and a study of latanoprost for Menière’s disease. A Phase II study with Biovitrum collaboration was initiated for psoriasis treatment[1][2][5].

Therapeutic areas: OphthalmologyNeurologyDermatology
Modalities: Prostaglandin analoguesSmall molecules (e.g., latanoprost derivative JB991)
Industry: Biotech

Drug pipeline

1 asset

JB991

Discontinued

Partnerships

Biovitrum AB — collaboration on clinical development of JB991 for psoriasis[5][6]

Beyond the preview

Go deeper on Synphora AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synphora AB.

Explore the full profile